==== Front Sci Rep Sci Rep Scientific Reports 2045-2322 Nature Publishing Group UK London 77937 10.1038/s41598-020-77937-8 Article U.S. state correlations between oral health metrics and Alzheimer’s disease mortality, prevalence and subjective cognitive decline prevalence Scherer Rana X. 1 http://orcid.org/0000-0002-2612-0719Scherer Warren J. wjsmd@hotmail.com 2 1 grid.170430.10000 0001 2159 2859University of Central Florida, The Burnett Honors College, 12778 Aquarius Agora Drive, Orlando, FL 32816-1800 USA 2 grid.419584.5St. Luke’s Cataract & Laser Institute, 43309 U.S. Highway 19 N., Tarpon Springs, FL 34689 USA 1 12 2020 1 12 2020 2020 10 2096231 7 2020 17 11 2020 © The Author(s) 2020Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Given the association between periodontal disease (PdD) and Alzheimer’s disease (AD), we examined correlations between states’ age-adjusted AD mortality rates, AD prevalence, subjective cognitive decline (SCD) prevalence, and oral health data. Data sources include the Centers for Disease Control and Prevention, scientific literature, and oral health rankings formulated by WalletHub.com and Toothbrush.org. Pearson (r) or Spearman (rs) correlation coefficients were generated and evaluated. AD mortality rates correlate with dental visits (r = − 0.50, p = 0.0003), partial (r = 0.39, p = 0.005) or total (r = 0.44, p = 0.001) edentulism, WalletHub.com (rs = 0.30, p = 0.03) and Toothbrush.org (rs = 0.35, p = 0.01) rankings. AD prevalence correlates with dental visits (r = − 0.30, p = 0.03), partial (r = 0.55, p = 0.00003) or total (r = 0.46, p = 0.0009) edentulism, prevalence of any (r = 0.38, p = 0.006) or severe-stage (r = 0.46, p = 0.0009) PdD, and WalletHub.com (rs = 0.38, p = 0.006) rankings. SCD prevalence in adults aged ≥ 45 years correlates with dental visits (r = − 0.69, p < 0.00001), partial (r = 0.33, p = 0.02) or total (r = 0.37, p = 0.008) edentulism, prevalence of any (r = 0.53, p = 0.0001) or severe-stage (r = 0.57, p = 0.00002) PdD, WalletHub.com (rs = 0.53, p = 0.00008) and Toothbrush.org (rs = 0.60, p < 0.00001) rankings. State metrics indicative of compromised oral health correlate with AD mortality rates, AD prevalence and SCD prevalence. Subject terms NeuroscienceNeurologyissue-copyright-statement© The Author(s) 2020 ==== Body Introduction Recently, evidence has emerged associating periodontal disease (PdD) with the development of, and cognitive decline in, Alzheimer’s disease (AD)1–7. Direct causation has not been definitively established; however, the preponderance of research points to a causative relationship between PdD and AD8. This comorbidity is consistent with the “antimicrobial protection hypothesis” of AD pathogenesis9–11. The hypothesis asserts that hallmark AD features, including extracellular amyloid-beta (Aβ) plaques, hyper-phosphorylation of tau protein, formation of intracellular neurofibrillary tangles, resultant neuroinflammation and neurodegeneration, are due to host responses to central nervous system (CNS) invasion by pathogens and/or their virulence factors11–15. Key to the immune response to CNS infection is Aβ itself. Once thought to be an incidental catabolic byproduct without a normal physiological role, Aβ has been shown to function as an antimicrobial peptide, a component of the innate immune system16. In the CNS, Aβ binds and disrupts bacterial, viral, and fungal cell membranes, resulting in aggregation and agglutination of pathogenic organisms17–22. Investigations have shown that Aβ production is induced by exposure to pathogens, their virulence factors and/or chronic neuroinflammation23–25. Accordingly, Aβ represents an immediate and continued physiological response to invading microorganisms, stimulating chronic neuroinflammation and subsequent compromise of blood–brain-barrier function25–27. Over time, this innate immune response, fueled by continued exposure to bacterial virulence factors, chronic CNS infection, or CNS pathogen reactivation, serves to irreversibly prime microglia to switch into an aggressive, pro-inflammatory state28–31. Consistent with age-dependency of AD development, CNS microglial responses to inflammatory challenge are similarly age-dependent. In young brains, microglial activation is associated with a reparative inflammatory response whereas in aged brains, an exacerbated inflammatory response occurs, resulting in proinflammatory microglial priming, neuronal death, synaptic loss, and cognitive decline32,33. Age-related, microglial-associated neurophysiological deficits have also been demonstrated by the inability to generate long-term potentiation, a cellular correlate for learning and memory, in the hippocampus of systemically-inflamed middle-aged, but not young rats34. Further supporting the role of microglia in this process, these investigators report that minocycline, an inhibitor of microglial activation, restored long term potentiation in systemically-inflamed middle-aged rats. PdD is a nonreversible, chronic, infectious, systemic inflammatory condition characterized by gram-negative polymicrobial dysbiosis of the sub-gingival microbiome28. Within the subgingival pocket, colonization by causative organisms such as Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola facilitates biofilm formation and PdD development35,36. The host’s exuberant systemic immunologic response to these pathogens results in destruction of gingival connective tissue, resorption of tooth-supporting alveolar bone and tooth loss37,38. Once PdD is established, dental procedures, brushing, flossing, or chewing can induce transient bacteremia, and planktonic dissemination of organisms and their shed outer membrane vesicles to distant organs and tissues, including the heart, liver, brain, coronary and peripheral arteries39–44. Specific to AD, P.gingivalis and its virulence factors, e.g. lipopolysaccharide and gingipains, which are cysteine-proteases associated with bacterial outer membrane and shed membrane vesicles, have been identified in AD brains and in cerebral spinal fluid of suspected AD patients25,45. Furthermore, serum antibody levels against P. gingivalis are increased in AD patients compared to non-AD controls46,47. Repeat episodes of PdD-induced bacteremia provide microorganisms and virulence factors with a hematogenous route to the CNS across a blood–brain barrier compromised by chronic inflammation, or alternatively, direct CNS invasion via the trigeminal nerve or olfactory tract48–50. SCD is defined as a self-experienced, persistent decline in cognitive capacity relative to a previously normal status51. First described in 1982, SCD is one of the earliest detectable risk factors for AD development52–55. Although SCD patients exhibit normal responses to cognitive tasks, functional magnetic resonance imaging studies have revealed aberrant brain activation patterns and compensatory cortical hyperactivation compared to controls56. Similar to AD, SCD is associated with CNS Aβ deposition and amyloid status in SCD is predictive of self-perceived cognitive state, current cognition and future cognitive decline57–60. Studies have confirmed comorbid relationships between AD prevalence, progression and severity, and PdD in select cohorts2,4,7,46,61–65. In a large cohort, Chen et al. recently discovered that patients with a 10 year history of PdD had a two-fold greater risk of developing AD compared to patients without PdD7. Unlike AD, little is known regarding the relationship between PdD and SCD; however, one small study has reported a positive correlation66. No previous study has analyzed associations between AD, SCD and PdD on a national level in the U.S. via comparisons of state-specific population data. The present study, utilizing state epidemiological data derived from governmental agencies, and scientific literature, is the first to examine U.S. state relationships between AD, SCD and oral health. Materials and methods All methods were carried out in accordance with relevant guidelines and regulations. All experimental protocols were reviewed and approved by the Office of the Medical Directorate, St. Luke’s Cataract & Laser Institute, Tarpon Springs, FL. Because individual patients did not participate as subjects in this research, informed consent was not applicable to the present study. All third party data utilized in this study is available free of charge in the public domain from online databases and government websites (see references for each dataset). For all 50 U.S. states, age-adjusted AD mortality, age-adjusted AD prevalence, SCD and oral health status data were obtained from several sources. Age-adjusted AD 2016 mortality rates were acquired from the Centers for Disease Control and Prevention (CDC) National Center for Health Statistics website67. Estimates of states’ age-adjusted AD prevalence were obtained from a study by Koller and Bynam which reviewed records of 4.8 million U.S. Medicare beneficiaries across all U.S. states68. State-specific SCD prevalence rates in adults aged ≥ 45 years were obtained from a study of 227,393 respondents across the U.S69. Because CDC oral health data and CDC age-adjusted AD mortality rates were subdivided by gender, a gender-based analysis for these data was also performed. All data used for analysis provided in spreadsheet format in Online Resource 1. Oral health data reporting percentage of adults visiting a dental clinic and adults > 65 years who have lost all, or ≥ 6 teeth were acquired from the CDC Oral Health Data by Location which completes 400,000 adult interviews each year70. State PdD prevalence rates were obtained from a study by Eke et al. which utilized CDC data from the National Health and Nutrition Examination Survey and Behavioral Risk Factor Surveillance System71. Statistics regarding state water fluoridation rates were obtained from the Office of Disease Prevention and Health Promotion72. Data from two national, non-peer-reviewed online state oral health ranking scales developed by WalletHub.com and Toothbrush.org were utilized for comparison to AD and SCD data73,74. The WalletHub.com scale, devised by 7 dental health researchers, evaluated state dental health across two key dimensions, “dental habits and care”, and “oral health”. These dimensions utilized 26 weighted metrics to generate composite U.S. state oral health scores. The Toothbrush.org ranking system evaluated state oral health status utilizing 20 metrics. Similar to WalletHub.com, the Toothbrush.org state rating system generated composite state oral health rankings based on “dental habits & care” and “oral health. In order to determine whether the WalletHub.com and Toothbrush.org rankings were consistent, a Bland Altman analysis was performed on the ranking data. Upper and lower limits of agreement were calculated by multiplying the standard deviation by (+) or (−) 1.96, respectively. State-specific age-adjusted AD mortality rates, age-adjusted AD prevalence data and SCD prevalence data were compared to corresponding oral health data to determine whether there existed significant relationships between state AD, SCD and oral health data. Pearson (r) or Spearman rank (rs), correlation coefficients, were calculated and tested (two-tailed) for statistical significance (p-value ≤ 0.05) against the null hypothesis of no correlation, H0: ρ = 0 using a standard table of critical values for r. Ranked data from WalletHub.com and Toothbrush.org were evaluated using Spearman rank correlation coefficients. Microsoft Excel was used to calculate correlation coefficients and generate scatter plots. It has been reported by some authors that the Pearson correlation is robust and can withstand violations of assumptions such as normality whereas others state that highly non-normal data distributions can reduce r values and inflate Type I error rates75. Given that non-normal data distributions could potentially affect r, a Kolmogorov–Smirnov test statistic (D) was calculated for each data set to determine whether it is normally distributed. A corresponding p-value ≤ 0.05 indicates that the data set is not normally distributed. Results The Kolmogorov–Smirnov test was performed on all Pearson-analyzed data sets to access normality. The age-adjusted AD mortality rates (D = 0.086; p value = 0.73), age-adjusted AD prevalence (D = 0.094; p value = 0.83), and SCD prevalence (D = 0.107; p value = 0.58) data sets were all found to be normally distributed. The CDC oral health survey data sets addressing the percentage of adults who had visited a dentist during the previous year (D = 0.081; p value = 0.88), the percentage of adults > age 65 years who had lost all of their teeth (D = 0.121; p value = 0.42), and the percentage of adults > age 65 years who had lost ≥ 6 teeth (D = 0.099; Pp value = 0.67) were found to be normally distributed. The U.S. all-stage PdD prevalence (D = 0.095; p value = 0.73) and severe-stage PdD prevalence (D = 0.094; p value = 0.73) data sets were found to be normally distributed. In summary, all data sets utilized for Pearson correlation coefficient analysis in the present study were found to be normally distributed. For each state, 2016 CDC oral health survey data addressed the percentage of adults who had visited a dentist during the previous year, the percentage of adults > age 65 years who had lost all of their teeth, and the percentage of adults > age 65 years who had lost ≥ 6 teeth (Table 1, Fig. 1). There were significant negative correlations between the percentage of adults who visited a dentist and age-adjusted AD mortality rates (r = − 0.50; p value = 0.0003), age-adjusted AD prevalence (r = − 0.30; p value = 0.03), and SCD prevalence (r = − 0.69; p value < 0.00001). There were significant positive correlations between the percentage of adults > age 65 years who had lost all of their teeth and age-adjusted AD mortality rate (r = 0.44; p value = 0.001), age-adjusted AD prevalence (r = 0.46; p value = 0.0009), and SCD prevalence (r = 0.37; p value = 0.008). Similarly, there were also significant positive correlations between the percentage of adults > age 65 years who had lost ≥ 6 teeth and age-adjusted AD mortality rate (r = 0.39; p value = 0.005), age-adjusted AD prevalence (r = 0.55; p value = 0.00003), and SCD prevalence (r = 0.33; p value = 0.018).Table 1 U.S. state-specific age-adjusted AD mortality rates, age-adjusted AD prevalence, SCD prevalence vs. oral health parameters. Oral Health Data Age-adjusted AD mortality rate Age-Adjusted AD Prevalence SCD Prevalence (≥ 45 years) r p-value r p-value r p-value % visiting dentist, past year all adults − 0.50 0.0003 − 0.30 0.03 − 0.69 < 0.00001 females − 0.52 0.0001 males − 0.42 0.003 % lost all teeth, > 65 years all adults 0.44 0.001 0.46 0.0009 0.37 0.008 females 0.43 0.001 males 0.37 0.007 % lost ≥ 6 teeth, > 65 years all adults 0.39 0.005 0.55 0.00003 0.33 0.02 females 0.36 0.009 males 0.34 0.02 All-stage PdDa prevalence 0.08 0.57 0.38 0.006 0.53 0.0001 Severe-stage PdD prevalence 0.15 0.30 0.46 0.0009 0.57 0.00002 WalletHub.com oral health overall rankingb 0.30 0.03 0.38 0.006 0.53 0.00008 Toothbrush.org oral health overall rankingb 0.35 0.01 0.25 0.08 0.60 < 0.00001 % Drinking water fluoridation 0.09 0.55 0.07 0.63 − 0.01 0.99 AD Alzheimer’s disease, SCD Subjective cognitive decline. aPeriodontal disease. br = Spearman correlation coefficient for ranked data (rs). Figure 1 CDC dementia data v CDC oral health metrics. Scatter-plots showing correlations between state-specific age-adjusted AD mortality rates, age-adjusted AD prevalence, SCD prevalence and CDC data regarding state population percent visiting a dentist during the past year, and percentage of adults > 65 years who have lost all or ≥ 6 teeth. Each point represents data from one U.S. state. The Pearson correlation coefficient (r) and corresponding P-value are presented for each correlation. AD Alzheimer’s disease, SCD subjective cognitive decline, CDC Centers for Disease Control and Prevention. Gender-based, age-adjusted AD mortality rate data showed similarly significant correlations with corresponding oral health data regarding percentage of females (r = − 0.52; p value = 0.0001) or males (r = − 0.42; p value = 0.002) visiting a dentist or dental clinic during the previous year, percentage of females (r = 0.43; p value = 0.001) or males (r = 0.37; p value = 0.007) > age 65 years who have lost all their teeth, and percentage of females (r = 0.36; p value = 0.009) or males (r = 0.34; p value = 0.02) > age 65 years who had lost ≥ 6 teeth (Table 1). Associations between all-stage PdD prevalence and severe-stage PdD prevalence were compared to age-adjusted AD mortality rate, age-adjusted AD prevalence and SCD prevalence (Table 1 and Fig. 2). No significant correlation was found between age-adjusted AD mortality rate and all-stage PdD prevalence (r = 0.08; p value = 0.56) or severe PdD prevalence (r = 0.15; p value = 0.30). Significant correlations were found between total PdD prevalence and age-adjusted AD prevalence (r = 0.38; p value = 0.006) and SCD prevalence (r = 0.53; p value = 0.0001). Significant correlations were found between severe PdD prevalence and age-adjusted AD prevalence (r = 0.46; p value = 0.0009) and SCD prevalence (r = 0.57; p value = 0.00002).Figure 2 CDC dementia data v PdD prevalence data. Scatter-plots showing correlations between state-specific age-adjusted AD mortality rates, age-adjusted AD prevalence, SCD prevalence and state PdD prevalence data for all-stages of PdD and severe-stage PdD. Each point represents data from one U.S. state. The Pearson correlation coefficient (r) and corresponding P-value are presented for each correlation. AD Alzheimer’s disease, SCD subjective cognitive decline, PdD periodontal disease, CDC Centers for Disease Control and Prevention. WalletHub.com and Toothbrush.org U.S. state oral health rankings were compared to respective age-adjusted AD mortality rate, age-adjusted AD prevalence and SCD prevalence (Table 1, Fig. 3). The WalletHub.com total oral health rankings were found to be significantly correlated with age-adjusted AD mortality rate (rs = 0.30; p value = 0.03), age-adjusted AD prevalence (rs = 0.38; p value = 0.006) and SCD prevalence (rs = 0.53; p value = 0.00008). The Toothbrush.org total oral health rankings were significantly correlated with age-adjusted AD mortality rate (rs = 0.35; p value = 0.01) and SCD prevalence (rs = 0.60; p value < 0.00001), however, the correlation with age-adjusted AD prevalence (rs = 0.25) did not reach significance (p value = 0.08). In order to determine whether these two state-by-state ranking systems were consistent with one another, a Bland Altman analysis was performed and revealed no significant differences (r = 0, p-value) between the Toothbrush.org and WalletHub.com state rankings (Fig. 4).Figure 3 CDC dementia data v State oral health ranks. Scatter-plots showing correlations between state-specific age-adjusted AD mortality rates, age-adjusted AD prevalence, SCD prevalence and WalletHub.com and Toothbrush,org state oral health rankings. Each point represents data from one U.S. state. The Spearman correlation coefficient (rs) and corresponding p-value are presented for each correlation. AD Alzheimer’s disease, SCD subjective cognitive decline, CDC Centers for Disease Control and Prevention. Figure 4 Bland Altman analysis comparing Toothbrush.org and WalletHub.com oral health ranking systems. No significant differences (r = 0, p-value = 1.0) were found between the WalletHub.com and Toothbrush.org ranking systems. Dotted lines represent 95% upper (17.56) and lower (− 17.56) limits of agreement. Bias = 0, S.D. =  ± 8.96. Drinking-water fluoridation, which reduces dental caries but is ineffective against PdD, was utilized as a negative control and examined as a factor associated with AD and SCD (Table 1). No significant correlations were found between the percentage of each states’ population served by fluoridated drinking water and age-adjusted AD mortality rate (r = 0.09; p value = 0.60), age-adjusted AD prevalence (r = 0.07; p value = 0.63) or SCD prevalence (r = − 0.003; p value = 0.99) (Table 1). Additionally, no correlations were found between the percentage of each states’ population that is served by fluoridated drinking water and all-stage PdD prevalence (r = − 0.04; p value = 0.81) or severe stage PdD prevalence (r = 0.005; p value = 0.97), confirming that state water fluoridation rates are unrelated to PdD prevalence. Discussion Utilizing state-specific, epidemiologic data, we conducted a nationwide correlational analysis examining possible associations between age-adjusted AD mortality rates, age-adjusted AD prevalence, SCD prevalence and oral health metrics relevant to PdD in the U.S. The rationale underlying these comparisons stems from the “antimicrobial protection hypothesis” of AD and recent investigations linking CNS infection, particularly the chronic, recurring infection that is pathognomonic of PdD, with the development and progression of AD. All correlations between CDC oral health data and dementia metrics were statistically significant; however, the strongest association existed between SCD prevalence and the percentage of respondents who visited a dental clinic during the previous year. This finding indicates that regular dental care is associated with a lower SCD prevalence among adults ≥ 45 years; however, it is not clear if the underlying cause of the association is due specifically to a reduction in the severity of PdD. Future research comparing oral health habits and dental health visits among SCD patients diagnosed with PdD versus controls could provide additional information. Given that SCD patients are generally younger than AD patients, establishment of a causative link between SCD and PdD could dramatically impact future medical and economic burdens of AD via policies and programs that address timely, routine dental prophylaxis. It is known that PdD is the main cause of tooth loss in middle aged and older adults76. With regard to tooth loss and edentulous condition among patients older than 65 years, the strongest correlations were observed with age-adjusted AD mortality rates and age-adjusted AD prevalence compared to SCD prevalence. This finding is not unexpected as the AD data comparison reflects a similar age group (i.e.; adults aged 65 + years) compared to the SCD prevalence data (adults ≥ 45 years). These findings are in general agreement with previous studies regarding AD and tooth loss77. Stein et al. found that tooth loss due to PdD doubles the risk of onset of AD78. A recent meta-analysis performed by Dioguardi et al. reported results with increased rates of partial tooth loss (hazard ratio: 1.52) and complete edentulous condition (hazard ratio: 2.26) amongst AD patients compared to controls79. These finding have been supported by other cohort studies. Specifically, the Hisayama study reported correlation between the loss of dental elements and dementia caused specifically by AD, as significant correlations were not found for dementia of vascular origin80. Additionally, the simple absence of teeth did not impact Aβ levels or hippocampal pyramidal cells in transgenic AD model mice whose molar teeth were surgically extracted81. With regard to gender and tooth loss, we found similar, significant correlations between age-adjusted AD mortality rates and CDC oral health data for both males and females. State prevalence of any-stage PdD, and severe-stage PdD were found to correlate significantly with both age-adjusted AD prevalence and SCD prevalence. However, no significant associations were found between any-stage or severe-stage PdD prevalence and age-adjusted AD mortality rates. A plausible explanation for this seemingly contradictory finding may be due to confounding effects of P. gingivalis and other PdD pathogen-induced mortality from diseases of organ systems other than the CNS. For example, it has been established that in addition to brain, P. gingivalis can migrate to other systemic sites, such as the cardiovascular system and liver40,41. Several studies have reported the presence of PdD pathogens in coronary atheromatous plaques from myocardial infarction patients and all clinically normal areas of coronary and femoral arterial wall samples from patients with a history cardiovascular disease were found to be colonized by P gingivalis42,82. Furthermore, viable PdD pathogens have been cultured from atherosclerotic plaques83. Clinical and epidemiological studies have demonstrated that PdD contributes to increased mortality from heart failure, ischemic heart disease, peripheral vascular disease, stroke, cancer and pneumonia84–92. All of these conditions are also common in elderly patients afflicted with AD. Therefore, mortality due to myocardial infarction, stroke, cancer or pneumonia in a mildly or moderately affected AD patient would necessitate listing the official “cause of death” as an entity other than AD. This reasoning may help to explain why AD prevalence, but not AD mortality, is correlated with PdD prevalence. The strongest state-by-state correlations existed between PdD (all-stage or severe-stage) prevalence and SCD prevalence. Because active PdD has been shown to result in continued cognitive decline in AD, aggressive PdD treatment may help to slow or reverse cognitive changes in younger patients with SCD. Once approved, another potential option could include treatment with oral gingipain inhibitors which have been shown to reduce CNS bacterial load, block Aβ production, reduce neuroinflammation, and rescue hippocampal neurons in a tissue culture and mouse model25. Although not specific for PdD, U.S. state rankings from two independent oral health evaluation systems formulated by WalletHub.com and Toothbrush.org were compared to corresponding age-adjusted AD mortality rates, age-adjusted AD prevalence and SCD prevalence. There were significant correlations between WalletHub.com composite state oral health rankings and age-adjusted AD mortality rates, age-adjusted AD prevalence and SCD prevalence. Similarly, significant correlations were found between Toothbrush.org composite state oral health rankings and respective age-adjusted AD mortality rates and SCD prevalence. Given the multi-factorial parameters incorporated into these oral health rating systems, the significance of the associations between state oral health scores and corresponding AD and SCD state epidemiological data is remarkable. Similar state-based ranking scales including factors more specific to PdD-related oral health such as tooth loss, bleeding on probing testing, periodontal pocket depth and degree of gingival recession might be expected to generate even stronger correlations with AD and SCD epidemiological data. The association between water fluoridation and age-adjusted AD mortality rates, AD prevalence and SCD prevalence was also examined. The addition of fluoride to public water supplies acts to reduce tooth decay and does not impact PdD93. The percent of state populations receiving fluoridated water varies across the U.S. We found no correlation between the percent of each state’s population served by water fluoridation and corresponding state AD or SCD data. This finding supports the hypothesis that the correlations between oral health metrics and AD data observed in this study are specific to PdD rather than other dental conditions such as caries. There are limitations of the present study. Due to the disparate nature and sources of the data sets, it was impossible to control for, or adjust for all possible confounding variables, such as economic or educational status, medical comorbidities, ethnicity or age. In certain cases, similarly aged groups were directly compared (e.g.: CDC data regarding edentualism in adults aged 65 + v. AD mortality or prevalence) whereas in other cases, the dataset referred to adults of all-ages (e.g.: CDC data reporting percentage of adults visiting a dentist). Unfortunately, datasets adjusted for all possible confounding variables are simply not available. However, given the levels of significance of our findings, we contend that the adult datasets from high-risk (high mortality and/or prevalence) AD states represent populations that are at greater risk for developing AD or cognitive decline later in life. Other limitations include the inability to conclusively attribute a clinical causation between PdD and AD, limited sample sizes of cross-sectional datasets relative to state populations, and possible inherent biases of the Toothbrush.org and WalletHub.com oral health rankings. Agreement between the results of the Toothbrush.org and Wallethub.com ranking scales based on Bland Altman analysis obviates some concerns regarding bias of either ranking system. Additionally, CDC data are self-reported and could be biased or inaccurate due to regional differences in survey-response behavioral patterns. However, the sampling of separate cohorts (i.e.: all adults v adults > 65 years and variability of questions (e.g.: dental visits v tooth loss), produced responses that consistently associate AD and SCD with poor oral health. Given these circumstances, it is unlikely that the correlations observed between AD data and CDC oral health data are due solely to regionally-related survey response bias. It is established that PdD is the main etiology underlying tooth loss in middle-aged and elderly adults, however, CDC oral health-related data sets would necessarily include other oral health-related etiologies of tooth loss in addition to PdD72. These conditions include trauma, caries, xerostomia, and chronic enamel erosion. One would expect that inclusion of non-PdD-related conditions would serve to confound, dilute and decrease associations between PdD and AD or SCD. However, despite the inability to exclude PdD-unrelated oral conditions from data sets, strong associations with AD and SCD data were still demonstrated. Additionally, several PdD-associated conditions such as stroke, ischemic heart disease, heart failure and peripheral vascular disease are also frequently encountered in AD patients. The presence or absence of any of these conditions could conceivably confound the results of the present study. Unfortunately, it was not possible to consider these effects as the cross-sectional epidemiological data available for this study did not include information on these comorbid conditions. In conclusion, significant correlations between state age-adjusted AD mortality, age-adjusted AD prevalence, SCD prevalence and statewide indicators of poor oral health in the U.S were found. Because PdD is a modifiable risk factor, government and private insurance programs or initiatives that positively impact PdD prevalence and severity could substantially reduce the clinical, social and financial burden of AD. Supplementary information Supplementary Information. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary information is available for this paper at 10.1038/s41598-020-77937-8. Acknowledgements We would like to thank Susan B. Udin, Ph.D., Professor, Dept. of Physiology, University at Buffalo, Buffalo, NY, for her help in editing the manuscript. Author contributions W.J.S.: Study concept, data collection and analysis, writing, design of figures and tables. R.X.S.: Study concept, data collection, writing, statistical analysis. Data availability All data used available in public domain online. Original spreadsheet for data analysis submitted as supplementary material. Competing interests The authors declare no competing interests. ==== Refs References 1. Kamer AR Craig RG Dasanayake AP Brys M Glodzik-Sobanska L de Leon MJ Inflammation and Alzheimer’s disease: possible role of periodontal diseases Alzheimers Dement. 2008 4 4 242 250 10.1016/j.jalz.2007.08.004 18631974 2. Noble JM Scarmeas N Celenti RS Elkind MS Wright CB Schupf N Papapavou PN Serum IgG antibody levels to periodontal microbiota are associated with incident Alzheimer disease PLoS ONE 2014 9 12 e114959 10.1371/journal.pone.0114959 25522313 3. Gaur S Agnihotri R Alzheimer’s disease and chronic periodontitis: is there an association? Geriatr. Gerontol. 2015 15 4 391 404 4. Ide M Harris M Stevens A Sussams R Hopkins V Cuilliford D Fuller J Ibbett P Raybould R Thomas R Puenter U Teeling J Perry VH Holmes C Periodontitis and cognitive decline in Alzheimer’s disease PLoS ONE 2016 11 3 e0151081 10.1371/journal.pone.0151081 26963387 5. Noble JM Borrell LN Papapanou PN Elkind MS Scarmeas N Wright CB Periodontitis is associated with cognitive impairment among older adults: analysis of NHANES-III J. Neurol. Neurosurg. Psychiatry 2009 80 11 1206 1211 10.1136/jnnp.2009.174029 19419981 6. Leira Y Dominguez C Seoane J Seoane-Romero J Pias-Peleteiro JM Takkouche B Blanco J Aldrey JM Is periodontal disease associated with Alzheimer’s disease? A systematic review with meta-analysis Neuroepidemiology 2017 48 1–2 21 31 10.1159/000458411 28219071 7. Chen CK Wu YT Chang YC Association between chronic periodontitis and the risk of Alzheimer’s disease: a retrospective, population-based, matched-cohort study Alzheimers Res. Ther. 2017 9 1 56 10.1186/s13195-017-0282-6 28784164 8. Singhrao SK Olsen I Assessing the role of Porphyromonas gingivalis in periodontitis to determine a causative relationship with Alzheimer’s disease J. Oral Microbiol. 2019 11 1 1563405 10.1080/20002297.2018.1563405 30728914 9. Itzhaki RF Lathe R Balin BJ Ball MJ Bearer EL Braak H Bullido MJ Carter C Clerici M Cosby SL Del Tredici K Field H Fulop T Grassi C Griffin WS Haas J Hudson AP Kamer AR Kell DB Licastro F Letenneur L Lovheim H Mancuso R Miklossy J Otth C Palamara AT Perry G Preston C Pretorius E Strandberg T Tabet N Taylor-Robinson SD Whittum-Hudson JA Microbes and Alzheimer’s disease J. Alzheimers Dis. 2016 51 4 979 984 10.3233/JAD-160152 26967229 10. Fulop T Witkowski JM Bourgade K Khalil A Zerif E Larbi A Hirokawa K Pawelec G Bocti C Lacombe G Dupuis G Frost EH Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer’s? Front. Aging Neurosci. 2018 10 224 10.3389/fnagi.2018.00224 30087609 11. Sochocka M Zwolinska K Leszek J The infectious etiology of Alzheimer’s disease Curr. Neuropharmacol. 2017 15 7 996 1009 10.2174/1570159X15666170313122937 28294067 12. Kitazawa M Oddo S Yamasaki TR Green KN LaFerla FM Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease J. Neurosci. 2005 25 39 8843 8853 10.1523/JNEUROSCI.2868-05.2005 16192374 13. Lee DC Rizer J Selenica ML Reid P Kraft C Johnson A Blair L Gordon MN Dickey CA Morgan D LPS-induced inflammation exacerbates phosphor-tau pathology in rTg4510 mice J. Neuroinflammation. 2010 7 56 10.1186/1742-2094-7-56 20846376 14. Kumar A Singh A Ekavali A review on Alzheimer’s disease pathophysiology and its management: an update Pharmacol. Rep. 2015 67 2 195 203 10.1016/j.pharep.2014.09.004 25712639 15. Krstic D Knuesel I Deciphering the mechanism underlying late-onset Alzheimer’s disease Nat. Rev. Neurol. 2013 9 1 25 34 10.1038/nrneurol.2012.236 23183882 16. Soscia SJ Kirby JE Washicosky KJ Tucker SM Ingelsson M Hyman B Burton MA Goldstein LE Duong S Tanzi RE Moir RD The Alzheimer’s disease-associated amyloid β-protein is an antimicrobial peptide PLoS ONE 2010 5 3 e9505 10.1371/journal.pone.0009505 20209079 17. Chauhan A Ray I Chauhan VP Interaction of amyloid beta-protein with anionic phospholipids: possible involvement of Lys28 and C-terminus aliphatic amino acids Neurochem. Res. 2000 25 3 423 429 10.1023/A:1007509608440 10761989 18. Kumar DK Choi SH Washicosky KJ Elmer WA Tucker S Ghofrani J Lefkowitz A McColl G Goldstein LE Tanzi RE Moir RD Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease Sci. Transl. Med. 2016 8 34 340 372 10.1126/scitranslmed.aaf1059 19. Ilievski V Zuchowska PK Green SJ Toth PT Ragozzino ME Le K Aljewari HW O’Brien-Simpson NM Reynolds EC Watanabe K Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice PLoS ONE 2018 13 10 e0204941 10.1371/journal.pone.0204941 30281647 20. Eimer WA Vijava Kumar DK Navalpur Shanmugam NK Rodrieguez AS MitchellT WKJ Gyorgy B Breakefield XO Tanzi RE Moir RD Alzheimer’s disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection Neuron 2018 99 1 56 63 10.1016/j.neuron.2018.06.030 30001512 21. Bourgade K LePage A Bocti C Witkowski JM Dupuis G Frost EH Fulop T Protective effect of amyloid-β peptides against herpes simplex virus-1 infection in a neuronal cell culture model J. Alzheimers Dis. 2016 50 4 1227 1241 10.3233/JAD-150652 26836158 22. White MR Kandel R Tripathi S Condon D Qi L Taubenberger J Hartshorn KL Alzheimer’s associated b-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes PLoS ONE 2014 9 7 e101364 10.1371/journal.pone.0101364 24988208 23. Sheng JG Bora SH Xu G Borchelt DR Price DL Koliatsos VE Lipopolysaccharide-induced neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice Neurobiol. Dis. 2003 14 1 133 145 10.1016/S0969-9961(03)00069-X 13678674 24. Lee JW Lee YK Yuk DY Choi DY Ban SB Oh KW Hong JT Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation J. Neuroinflammation 2008 5 37 10.1186/1742-2094-5-37 18759972 25. Dominy SS Lynch C Ermini F Nenedyk M Marczyk A Konradi A Nguyen M Haditsch U Raha D Griffin C Holsinger LJ Arastu-Kapur S Kaba S Lee A Ryder MI Potempa B Mydel P Hellvard A Adamowicz K Hastruk H Walker GD Reynolds EC Faull RL Curtis MA Dragunow M Potempa J Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for direct causation and treatment with small-molecule inhibitors Sci. Adv. 2019 5 1 3333 10.1126/sciadv.aau3333 26. Thurgur H Pinteaux E Microglia in the neurovascular unit: blood-brain barrier-microglia interactions after central nervous system disorders Neuroscience 2019 405 55 67 10.1016/j.neuroscience.2018.06.046 31007172 27. Diaz-Zuniga J Munoz Y Melgar-Rodriguez S More J Bruna B Lobos P Monasterio G Vernal R Paula-Lima A Serotype b of Aggregatibacter actinomycetemcomitans triggers pro-inflammatory responses and amyloid beta secretion in hippocampal cells: a novel link between periodontitis and Alzheimer’s disease? J. Oral. Microbiol. 2019 11 1 1586423 10.1080/20002297.2019.1586423 31044031 28. Teixeira FB Saito MT Matheus FC Prediger RD Yamada ES Maia CSF Lima RR Periodontitis and Alzheimer’s disease: a possible comorbidity between oral chronic inflammatory condition and neuroinflammation Front. Aging Neurosci. 2017 9 327 10.3389/fnagi.2017.00327 29085294 29. Block ML Hong JS Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism Prog. Neurobiol. 2005 76 2 77 98 10.1016/j.pneurobio.2005.06.004 16081203 30. Cestari JA Fabri GM Kalil J Nitrini R Jacob-Filho W de Siqueira JT de Siqueira SR Oral infections and cytokine levels in patients with Alzheimer’s disease and mild cognitive impairment compared with controls J. Alzheimers Dis. 2016 52 4 1479 1485 10.3233/JAD-160212 27104907 31. Wu Z Nakanishi H Connection between periodontitis and Alzheimer’s disease: possible roles of microglia and leptomeningeal cells . Pharmacol. Sci. 2014 126 1 8 13 10.1254/jphs.14R11CP 32. Cunningham C Hennessey E Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research Alzheimers Res. Ther. 2015 7 1 33 10.1186/s13195-015-0117-2 25802557 33. Wu Z Tokuda Y Zhang XW Nakanishi H Age-dependent responses of glial cells and leptomeninges during systemic inflammation Neurobiol. Dis. 2008 32 3 543 551 10.1016/j.nbd.2008.09.002 18848892 34. Liu X Wu Z Hayashi Y Nakanishi H Age-dependent neuroinflammatory responses and deficits in long-term potentiation in the hippocampus during systemic inflammation Neuroscience 2012 216 133 142 10.1016/j.neuroscience.2012.04.050 22554776 35. Page RC Kornman KS (1997) The pathogenesis of human periodontitis: an introduction Periodontol 2000 14 9 11 10.1111/j.1600-0757.1997.tb00189.x 36. Herbert BA Novince CM Kirkwood KL Aggregatibacter actinomycetemcomitans , a potent immunoregulator of the periodontal host defense system and alveolar bone homeostasis Mol. Oral Microbiol. 2016 31 3 207 227 10.1111/omi.12119 26197893 37. Armitage GC Development of a classification system for periodontal diseases and conditions Ann. Periodontol. 1999 4 1 1 6 10.1902/annals.1999.4.1.1 10863370 38. Bansal T Dhruvakumar D Pandey A Comparative evaluation of C-reactive protein in peripheral blood of patients with healthy gingival, gingivitis and chronic periodontitis: a clinical and particle-enhanced turbidometric immune-analysis J. Indian Soc. Periodontol. 2014 18 6 739 743 10.4103/0972-124X.147410 25624631 39. Forner L Larsen T Kilian M Holmstrup P Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation J. Clin. Periodontol. 2006 33 6 401 407 10.1111/j.1600-051X.2006.00924.x 16677328 40. Mahendra J Mahendra L Kurian VM Jaishankar K Mythilli R Prevalence of periodontal pathogens in coronary atherosclerotic plaque of patients undergoing coronary artery bypass graft surgery J. Maxillofac. Oral Surg. 2009 8 2 108 113 10.1007/s12663-009-0028-5 23139486 41. Ishikawa M Yoshida K Okamura H Ochiai K Takamura H Fujiwara N Ozaki K (2013) Oral Porphyromonas gingivalis translocates to the liver and regulates hepatic glycogen synthesis through the Akt/GSK-3 signaling pathway Biochim. Biophys. Acta 1832 12 2035 2043 42. Mougeot JC Stevens CB Paster BJ Brennan MT Lockhart PB Mougeot FKB Porphyromonas gingivalis is the most abundant species detected in coronary and femoral arteries J. Oral Microbiol. 2017 9 1 1281562 10.1080/20002297.2017.1281562 28326156 43. Singhrao SK Olsen I Are Porphyromonas gingivalis outer membrane vesicles microbullets for sporadic Alzheimer’s disease manifestation? J. Alzheimers Dis. Rep. 2018 2 1 219 228 10.3233/ADR-180080 30599043 44. Wu H Moser C Wang HZ Hoiby N Song ZJ Strategies for combating bacterial biofilm infections Int. J. Oral Sci. 2015 7 1 1 7 10.1038/ijos.2014.65 25504208 45. Poole S Singhrao SK Kesavalu L Curtis MA Crean S Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer’s disease brain tissue J. Alzheimers Dis. 2013 36 4 665 677 10.3233/JAD-121918 23666172 46. Sparks Stein P Steffen MJ Smith C Jicha G Ebersole JL Abner E Dawson D Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease Alzheimers Dement. 2012 8 3 196 203 10.1016/j.jalz.2011.04.006 22546352 47. Kamer AR Craing RG Pirraglia E Dasanayake AP Norman RG Boylan RJ Nehorayoff A Glodzik L Brys M de Leon MJ TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer’s disease patients and normal subjects J. Neuroimmunol. 2009 216 1–2 92 97 10.1016/j.jneuroim.2009.08.013 19767111 48. Riviere GR Riviere KH Smith KS Molecular and immunological evidence of Treponema in the human brain and their association with Alzheimer’s disease Oral Microbiol. Immunol. 2002 17 2 113 118 10.1046/j.0902-0055.2001.00100.x 11929559 49. Olsen I Singhrao SK Can oral infection be a risk factor for Alzheimer’s disease? J. Oral Microbiol. 2015 7 29143 10.3402/jom.v7.29143 26385886 50. Miklossy J Alzheimer’s disease: a neurospirochetosis. Analysis of the evidence following Koch’s and Hill’s criteria J. Neuroinflammation 2011 8 90 10.1186/1742-2094-8-90 21816039 51. Jessen F Amariglio RE van Boxtel M Breteler M Ceccaldi M Chételat G Dubois B Dufouil C Ellis KA van der Flier W Glodzik L van Harten AC de Leon MJ McHugh P Mielke MM Molinuevo JL Mosconi L Osorio RS Perrotin A Peterson RC Rabin LA Rami L Reisberg B Rentz DM Sachdev PS de la Sayette V Saykin AJ Scheltens P Shulman MB Slavin MJ Sperling RA Stewart R Uspenskaya O Vellas B Visser PJ Wagner M A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease Alzheimer’s Dement. 2014 10 6 844 852 10.1016/j.jalz.2014.01.001 24798886 52. Reisberg B Ferris SH deLeon MJ Crook T The global deterioration scale for assessment of primary degenerative dementia Am. J. Psychiatr. 1982 139 9 1136 1139 10.1176/ajp.139.9.1136 7114305 53. Mizuno A Ly M Aizenstein HJ A homeostatic model of subjective cognitive decline Brain Sci. 2018 8 12 10.3390/brainsci8120228 54. Mitchell AJ Beaumont H Ferguson D Yadeqarfar M Stubbs B Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis Acta Psychiatr. Scand. 2014 130 6 439 451 10.1111/acps.12336 25219393 55. Rabin LA Smart CM Amariglio RE Subjective cognitive decline in preclinical Alzheimer’s disease Annu. Rev. Clin. Psychol. 2017 13 369 396 10.1146/annurev-clinpsy-032816-045136 28482688 56. Rodda JE Dannhauser TM Cutinha DJ Shergill SS Walker Z Subjective cognitive impairment: increased prefrontal cortex activation compared to controls during an encoding task Int. J. Geriatr. Psychiatry 2009 24 8 865 874 10.1002/gps.2207 19259973 57. Amariglio RE Becker JA Carmasin J Wadsworth LP Lorius N Sullivan C Maye JE Gidicsin C Pepin LC Sperling RA Johnson KA Rentz DM Subjective cognitive complaints and amyloid burden in cognitively normal older adults Neuropsychologica 2012 50 12 2880 2886 10.1016/j.neuropsychologia.2012.08.011 58. Perrotin A Mormino EC Madison CM Hayenga AO Jaqust WJ Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly adults Arch. Neurol. 2012 69 2 223 229 10.1001/archneurol.2011.666 22332189 59. Snitz BE Weissfeld LA Cohen AD Lopez OL Nebes RD Aizenstein HJ McDade E Price JC Mathis CA Klunk WE Subjective cognitive complaints, personality and brain amyloid-beta in cognitively normal older adults Am. J. Geriatr. Psychiatry 2015 23 9 985 993 10.1016/j.jagp.2015.01.008 25746485 60. Vogel JW Varga Dolezalova M La Joie R Marks SM Schwimmer HD Landau SM Jagust WJ Subjective cognitive decline and b-amyloid burden predict cognitive change in healthy elderly Neurology 2017 89 19 2002 2009 10.1212/WNL.0000000000004627 28986416 61. Martande SS Pradeep AR Singh SP Kumari M Suke DK Raju AP Naik SB Singh P Guruprasad CN Chatterji A Periodontal health condition in patients with Alzheimer’s disease Am. J. Alzheimers Dis. Other Dement. 2014 29 6 498 502 10.1177/1533317514549650 62. Kim DH Jeong SN Lee JH Severe periodontitis with tooth loss as a modifiable risk factor for the development of Alzheimer, vascular, and mixed dementia: National Health Insurance Service: National Health Screening cohort . Periodontal Implant. Sci. 2020 50 5 303 312 10.5051/jpis.2000600030 63. de OliveiraAraujo R Villoria GEM Luiz RR Esteves JC Leao ATT Feres-Filho EJ Association between periodontitis and Alzheimer’s disease and its impact on the self-perceived oral health status: a case-control study Clin. Oral. Investig. 2020 5 2 10.1007/s00784-020-03489-w 64. Zhang S Yang F Wang Z Qian X Ji Y Gong L Ge S Yan F Poor oral health conditions and cognitive decline: Studies in humans and rats PLoS ONE 2020 15 7 e0234659 10.1371/journal.pone.0234659 32614834 65. Ryder MI Porphyromonas gingivalis and Alzheimer disease: Recent findings and potential therapies J. Periodontal 2020 91 Suppl 1 S45 S49 66. Holmer J Eriksdotter M Schultzberg M Pussinen PJ Buhlin K Association between periodontitis and risk of Alzheimer’s disease, mild cognitive impairment and subjective cognitive decline: a case-control study J. Clin. Periodontol. 2018 45 11 1287 1298 10.1111/jcpe.13016 30289998 67. Center for Disease Control and Prevention (CDC) National Center for Health Statistics (2016). https://www.cdc.gov/nchs/pressroom/sosmap/alzheimers_mortality/alzheimers_disease.htm. Accessed 31 Dec 2019. 68. Koller D Bynum JPW Dementia in the USA: State variation in prevalence J. Public Health 2015 37 4 597 604 69. Taylor CA Bouldin ED Mcguire LC Subjective cognitive decline among adults aged > 45 years: United States, 2015–2016 MMWR Morb. Mortal. Wkly. Rep. 2018 67 753 757 10.15585/mmwr.mm6727a1 30001562 70. Center for Disease Control and Prevention (CDC) Oral health Data 2016 (2016) https://www.cdc.gov/oralhealthdata/. Accessed 18 Dec 2019. 71. Eke PI Zhang X Lu H Wei L Thornton-Evans G Greenlund KJ Holt JB Croft JB Predicting periodontitis at state and local levels in the United States J. Dent. Res. 2016 95 5 515 522 10.1177/0022034516629112 26848071 72. Office of Disease Prevention and Health Promotion, State-level data (2014) Population served by community water systems with optimally fluoridated water in 2014 (percent). Accessed 18 Dec 2019. 73. McCann A. (2018) States the best & worst dental health. https://wallethub.com/edu/states-with-best-worst-dental-health/31498/#methodology. Accessed 18 Dec 2019. 74. Toothbrush.org. (2019) Which states have the best oral health in 2019? https://www.toothbrush.org/us-oralhealth/#1522615299403-de84557e-4a32. Accessed 18 Dec 2019. 75. Bishara AJ Hittner JB Testing the significance of a correlation with non-normal data: comparison of Pearson, Spearman, transformation, and resampling approaches Psychol. Method 2012 17 399 417 10.1037/a0028087 76. Klock KS Haugejorden O Primary reasons for extraction of permanent teeth in Norway: changes from 1968 to 1988 Community Dent. Oral Epidemiol. 1991 19 6 336 341 10.1111/j.1600-0528.1991.tb00183.x 1764900 77. Kondo K Niino M Shido K A case-control study of Alzheimer’s disease in Japan: significance of lifestyles Dementia 1994 5 6 314 326 7866485 78. Stein PS Desrosiers M Donegan SJ Yepes JF Kryscio RJ Tooth loss, dementia and neuropathology in the nun study J Am Dent Assoc 2007 138 10 1314 1322 10.14219/jada.archive.2007.0046 17908844 79. Dioguardi M Gioia GD Caloro GA Capocasale G Zhurakivska K Troiano G Lo Russo L Lo Muzio L The association between tooth loss and Alzheimer’s disease: a systemic review with meta-analysis of case control studies Dent. J. 2019 7 2 10.3390/dj7020049 80. Takeuchi K Ohara T Furuta M Takeshita T Shibata Y Hata J Yoshida D Yamashita Y Ninomiya T Tooth loss and risk of dementia in the community: the Hisayama study J. Am. Geriatr. Soc. 2017 65 5 e95 e100 10.1111/jgs.14791 28272750 81. Oue H Miyamoto Y Koretake K Okada S Doi K Jung CG Michikawa M Akagawa Y Tooth loss might not alter molecular pathogenesis in an aged transgenic Alzheimer’s disease model mouse Gerodontol 2016 33 3 308 314 10.1111/ger.12153 82. Joshi C Bapat R Anderson W Dawson D Hijazi K Cherukara G Detection of periodontal microorganisms in coronary atheromatous plaque specimens of myocardial infarction patients: a systematic review and meta-analysis Trends Cardiovasc. Med. 2019 19 30175 30176 83. Kozarov EV Dorn BR Shelburne CE Dunn WA Progulske-Fox A Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis Arteroscler. Thromb. Vasc. Biol. 2005 25 3 e17 18 10.1161/01.ATV.0000155018.67835.1a 84. Lee HU Choi EK Park JB Han KD Oh S Tooth loss predicts myocardial infarction, heart failure, stroke and death J. Dent. Res. 2019 98 2 164 170 10.1177/0022034518814829 30782090 85. Watt RG Tsakos G de Oliveira C Hamer M Tooth loss and cardiovascular disease mortality risk: results from the Scottish Health Survey PLoS ONE 2012 7 2 e30797 10.1371/journal.pone.0030797 22363491 86. Janket SJ Baird AE Chuang SK Jones JA Meta-analysis of periodontal disease and risk of coronary heart disease and stroke Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2003 95 5 559 569 10.1067/moe.2003.107 12738947 87. Bahekar AA Singh S Saha S Molnar J Arora R The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis Am. Heart J. 2007 154 5 830 837 10.1016/j.ahj.2007.06.037 17967586 88. Humphrey LL Fu R Buckley DI Freeman M Halfand M Periodontal disease and coronary heart disease incidence: a systemic review and meta-analysis J. Gen. Intern. Med. 2008 23 12 2079 2086 10.1007/s11606-008-0787-6 18807098 89. Wu T Trevisan M Genco RJ Dorn JP Falkner KL Sempos CT Periodontal disease and risk of cerebrovascular disease: the first national healthand nutrition examination survey and its follow-up study Arch. Inten. Med. 2000 160 18 2749 2755 10.1001/archinte.160.18.2749 90. Joshy G Arora M Korda RJ Chalmers J Banks E Is poor oral health a risk marker for incident cardiovascular disease hospitalization and all-cause mortality? Findings from 172630 participants from the prospective 45 and Up Study BMJ Open 2016 6 8 e012386 10.1136/bmjopen-2016-012386 27577588 91. Jansson L Kalkali H Mulk Niazi F Mortality rate and oral health: a cohort study over 44 years in the county of Stockholm Acta Odont. Scand. 2018 76 4 299 304 10.1080/00016357.2018.1423576 29320896 92. Iwasaki M Taylor GW Awano S Yoshida A Kataoka S Ansai T Nakamura H Periodontal disease and pneumonia mortality in haemodialysis patients: a 7-year cohort study J. Clin. Periodontol. 2018 4 1 38 45 10.1111/jcpe.12828 93. Centers for Disease Control and Prevention Recommendations for using fluoride to prevent and control dental caries in the United States MMWR Recomm Rep 2001 50 14 1 42